Switch theme
Sign up to access all valuation multiples
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
2011
130
LTM Revenue $245M
Last FY EBITDA $31.7M
$823M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Aurinia Pharmaceuticals has a last 12-month revenue (LTM) of $245M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Aurinia Pharmaceuticals achieved revenue of $235M and an EBITDA of $31.7M.
Aurinia Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Aurinia Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $245M | XXX | $235M | XXX | XXX | XXX |
| Gross Profit | $217M | XXX | $207M | XXX | XXX | XXX |
| Gross Margin | 88% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $31.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 13% | XXX | XXX | XXX |
| EBIT | $31.8M | XXX | $18.4M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $38.2M | XXX | $5.8M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Aurinia Pharmaceuticals's stock price is $8.
Aurinia Pharmaceuticals has current market cap of $1.1B, and EV of $823M.
See Aurinia Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $823M | $1.1B | XXX | XXX | XXX | XXX | $0.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Aurinia Pharmaceuticals has market cap of $1.1B and EV of $823M.
Aurinia Pharmaceuticals's trades at 3.5x EV/Revenue multiple, and 25.9x EV/EBITDA.
Equity research analysts estimate Aurinia Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aurinia Pharmaceuticals has a P/E ratio of 27.7x.
See valuation multiples for Aurinia Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV (current) | $823M | XXX | $823M | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 25.9x | XXX | XXX | XXX |
| EV/EBIT | 25.9x | XXX | 44.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 27.7x | XXX | 183.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 18.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAurinia Pharmaceuticals's last 12 month revenue growth is 14%
Aurinia Pharmaceuticals's revenue per employee in the last FY averaged $1.8M, while opex per employee averaged $1.4M for the same period.
Aurinia Pharmaceuticals's rule of 40 is -22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Aurinia Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Aurinia Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -22% | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 80% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aurinia Pharmaceuticals acquired XXX companies to date.
Last acquisition by Aurinia Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Aurinia Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Aurinia Pharmaceuticals founded? | Aurinia Pharmaceuticals was founded in 2011. |
| Where is Aurinia Pharmaceuticals headquartered? | Aurinia Pharmaceuticals is headquartered in United States of America. |
| How many employees does Aurinia Pharmaceuticals have? | As of today, Aurinia Pharmaceuticals has 130 employees. |
| Who is the CEO of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals's CEO is Mr. Peter S. Greenleaf. |
| Is Aurinia Pharmaceuticals publicy listed? | Yes, Aurinia Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals trades under AUPH ticker. |
| When did Aurinia Pharmaceuticals go public? | Aurinia Pharmaceuticals went public in 2009. |
| Who are competitors of Aurinia Pharmaceuticals? | Similar companies to Aurinia Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals's current market cap is $1.1B |
| What is the current revenue of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals's last 12 months revenue is $245M. |
| What is the current revenue growth of Aurinia Pharmaceuticals? | Aurinia Pharmaceuticals revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Aurinia Pharmaceuticals? | Current revenue multiple of Aurinia Pharmaceuticals is 3.4x. |
| Is Aurinia Pharmaceuticals profitable? | Yes, Aurinia Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
